Findings

What do systematic reviews say?

1,655 questions · 1,751 findings · 147 reviews · Pain, Palliative and Supportive Care

Sort:Best matchNewestHighest certainty Download CSV

No studies found 361 · 20.6%GRADE not reported 87 · 5%Very low 625 · 35.7%Low 367 · 21%Moderate 232 · 13.2%High 79 · 4.5%

Botulinum toxin type A vs other established prophylactic agent

Headache intensity (mean score) · adults with migraine

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 46 participants
Very low

Botulinum toxin type A vs other established prophylactic agent

Global impression of disease · adults with migraine

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 101 participants
Very low

Botulinum toxin type A vs other established prophylactic agent

Number experiencing adverse effects · adults with migraine

It is very uncertain whether botulinum toxin type A changes total number of participants experiencing an adverse event compared with other established prophylactic agent (very low certainty).

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
RR 0.76 [0.59, 0.98]
2 studies · 114 participants
Very low

Botulinum toxin type A vs placebo

Number of migraine days per month · adults with migraine

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1915 participants
Very low

Botulinum toxin type A vs placebo

Number of headache days per month: chronic migraine only · adults with migraine

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1384 participants
High

Botulinum toxin type A vs placebo

Migraine frequency Number of attacks · adults with migraine

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 2004 participants
Low

Botulinum toxin type A vs placebo

Headache intensity (mean score) · adults with migraine

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 209 participants
Very low

Botulinum toxin type A vs placebo

Global impression scale · adults with migraine

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low

Botulinum toxin type A vs placebo

Number experiencing adverse effects · adults with migraine

Botulinum toxin type A probably leads to higher total number of participants experiencing an adverse event compared with placebo (moderate certainty).

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
RR 1.28 [1.12, 1.47]
13 studies · 3325 participants
Moderate

Botulinum toxin type A vs other established prophylactic agent

Number of migraine days per month: chronic migraine only · adults with migraine

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Very low

Botulinum toxin type A vs other established prophylactic agent

Headache (frequency) · adults with migraine

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Very low

Exercise vs usual care

Falls · adults (18 years of age or older at diagnosis) living with and beyond cancer

1 finding from 1 review

Exercise for reducing falls in people living with and beyond cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 223 participants
Very low

Exercise vs usual care

Strength through equipment‐based measures: leg press (kg) strength · adults (18 years of age or older at diagnosis) living with and beyond cancer

1 finding from 1 review

Exercise for reducing falls in people living with and beyond cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 388 participants
Low

Exercise vs usual care

Strength through functional measures; Sit‐to‐Stand Test · adults (18 years of age or older at diagnosis) living with and beyond cancer

1 finding from 1 review

Exercise for reducing falls in people living with and beyond cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 214 participants
Very low

Exercise vs usual care

Flexibility: Sit‐and‐Reach Distance Test (cm) · adults (18 years of age or older at diagnosis) living with and beyond cancer

1 finding from 1 review

Exercise for reducing falls in people living with and beyond cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Exercise vs usual care

Balance: postural stability · adults (18 years of age or older at diagnosis) living with and beyond cancer

1 finding from 1 review

Exercise for reducing falls in people living with and beyond cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 127 participants
Very low

Exercise vs usual care

Balance: Backward Walk Test (seconds) · adults (18 years of age or older at diagnosis) living with and beyond cancer

1 finding from 1 review

Exercise for reducing falls in people living with and beyond cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 280 participants
Low

Exercise vs usual care

Adverse effect: fatigue · adults (18 years of age or older at diagnosis) living with and beyond cancer

1 finding from 1 review

Exercise for reducing falls in people living with and beyond cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 78 participants
Very low

Intervention not reported

The ability of OWSC, when seen to reach the colon on · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…

The review found no eligible studies for this question.

1 finding from 1 review

Oral water soluble contrast for malignant bowel obstruction 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

The rate of resolution of MBO with medical management only in patients receiving OWSC compared with those not receiving it (therapeutic). · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…

The review found no eligible studies for this question.

1 finding from 1 review

Oral water soluble contrast for malignant bowel obstruction 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found